Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Cancers of the gastrointestinal (GI) tract greatly contribute to the global cancer burden and cancer-related death. Claudin-18.2(CLDN18.2), a transmembrane protein, is a major component of tight junctions and plays an important role in the maintenance of barrier function. Its characteristic widespread expression in tumour tissues and its exposed extracellular loops make it an ideal target for researchers to develop targeted strategies and immunotherapies for cancers of the GI tract. In the present review, we focus on the expression pattern of CLDN18.2 and its clinical significance in GI cancer. We also discuss the tumour-promoting and/or tumour-inhibiting functions of CLDN18.2, the mechanisms regulating its expression, and the current progress regarding the development of drugs targeting CLDN18.2 in clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several CLDN18.2-targeting therapies have demonstrated efficacy in clinical trials for GI cancers, including antibodies, antibody-drug conjugates (ADC), and CAR-T cells (64–66).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [66]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 2×
“3 HER2/HER3 signalling pathway The HER family consists of four membrane-bound tyrosine kinase receptors with similar structures: HER1 (EGFR), HER2, HER3, and HER4 (63).”
BackgroundComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672 · cited 1×
“4 MicroRNA MicroRNAs (miRNAs) are a large family of small endogenous regulatory RNAs that regulate posttranscriptional regulators of gene expression (67, 68).”
BackgroundChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Lu, T. X., & Rothenberg, M. E. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.034 · Cited by 2,425
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K., & Tsukita, S. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.7.1539 · Cited by 2,095
Global Burden of 5 Major Types of Gastrointestinal Cancer
Arnold, M., Abnet, C. C., Neale, R. E., Vignat, J., Giovannucci, E. L., McGlynn, K. A., & Bray, F. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.068 · Cited by 2,027 · cited 1×
“4 million cancer-related deaths worldwide in 2018; these numbers correspond to over one-quarter (26%) of global cancer cases and over one-third (35%) of all cancer-related deaths (1).”
BackgroundBispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
Yan, H. H. N., Siu, H. C., Law, S., Ho, S. L., Yue, S. S. K., Tsui, W. Y., Chan, D., Chan, A. S., Ma, S., Lam, K. O., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.09.016 · Cited by 724
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., Zhang, M., Peng, Z., Zhou, J., Cao, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01800-8 · Cited by 604
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
Sahin, U., Koslowski, M., Dhaene, K., Usener, D., Brandenburg, G., Seitz, G., Huber, C., & Türeci, O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1547 · Cited by 501 · cited 1×
“2 protein is a highly selective gastric lineage marker expressed in short-lived differentiated cells but not the stem cell zone of stomach mucosa (43).”
BackgroundCurrent Progress in CAR-T Cell Therapy for Solid Tumors
Ma, S., Li, X., Wang, X., Cheng, L., Li, Z., Zhang, C., Ye, Z., & Qian, Q. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.34213 · Cited by 496
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., Vynnychenko, I., Dudov, A., Bazin, I., Bondarenko, I., Melichar, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.005 · Cited by 383
Yuan, L., Xu, Z.-Y., Ruan, S.-M., Mo, S., Qin, J.-J., & Cheng, X.-D. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01219-0 · Cited by 329
Self-citationNiimi, T., Nagashima, K., Ward, J. M., Minoo, P., Zimonjic, D. B., Popescu, N. C., & Kimura, S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7380-7390.2001 · Cited by 291 · cited 1×
“promotes the transactivation of claudin-18a1 expression, and mutation of each motif attenuates claudin-18a1 promoter activity by approximately one-half, while mutation of both sites nearly abolishes the transcriptional activity of the gene (60).”
BackgroundProtein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Isakov, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 270 · cited 1×
“In addition, PKC affects transcription factors in the nucleus and thus plays an important role in the regulation of gene expression (61).”
BackgroundTüreci, O., Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., Thuss-Patience, P., Ettrich, T., Arnold, D., Bassermann, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz199 · Cited by 248
Jiang, H., Shi, Z., Wang, P., Wang, C., Yang, L., Du, G., Zhang, H., Shi, B., Jia, J., Li, Q., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy134 · Cited by 247
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Singh, P., Toom, S., & Huang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0473-4 · Cited by 224 · cited 2×
“Both the C-terminus and the Nterminus of CLDN 18 are located in the cytoplasm (Figure 1) (6).”
BackgroundGaldy, S., Lamarca, A., McNamara, M. G., Hubner, R. A., Cella, C. A., Fazio, N., & Valle, J. W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9645-x · Cited by 209
Bispecific antibody based therapeutics: Strengths and challenges
Thakur, A., Huang, M., & Lum, L. G. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.004 · Cited by 183
Update on gastric cancer treatments and gene therapies
Biagioni, A., Skalamera, I., Peri, S., Schiavone, N., Cianchi, F., Giommoni, E., Magnelli, L., & Papucci, L. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09803-7 · Cited by 183 · cited 1×
“However, chemotherapy resistance and tumour progression and recurrence in cancer patients have become the most common causes of treatment failure (4).”
BackgroundZhou, B., Flodby, P., Luo, J., Castillo, D. R., Liu, Y., Yu, F.-X., McConnell, A., Varghese, B., Li, G., Chimge, N.-O., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci90429 · Cited by 180 · cited 2×
“1 results in increased lung size, progenitor cell proliferation, and tumourgenesis in mice (17).”
BackgroundSanada, Y., Oue, N., Mitani, Y., Yoshida, K., Nakayama, H., & Yasui, W. (2006) · The Journal of Pathology · doi:10.1002/path.1922 · Cited by 179
Sahin, U., Schuler, M., Richly, H., Bauer, S., Krilova, A., Dechow, T., Jerling, M., Utsch, M., Rohde, C., Dhaene, K., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.007 · Cited by 168
Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
Shim, H. (2020) · Biomolecules · doi:10.3390/biom10030360 · Cited by 166
Pellino, A., Brignola, S., Riello, E., Niero, M., Murgioni, S., Guido, M., Nappo, F., Businello, G., Sbaraglia, M., Bergamo, F., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111095 · Cited by 157 · cited 2×
“2 activation in metastatic lesions (lymph node and liver metastases) is comparable to that in primary lesions (26, 30, 31).”
BackgroundResultPrognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer
Shu, Y., Zhang, W., Hou, Q., Zhao, L.-Y., Zhang, S., Zhou, J., Song, X.-H., Zhang, Y., Jiang, D., Chen, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04907-0 · Cited by 155 · cited 2×
“Further studies have identified significant drug resistance acquired in CLDN18-ARHGAP26-introduced cell lines (51).”
BackgroundSelf-citationRecurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity
Yao, F., Kausalya, J. P., Sia, Y. Y., Teo, A. S. M., Lee, W. H., Ong, A. G. M., Zhang, Z., Tan, J. H. J., Li, G., Bertrand, D., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.020 · Cited by 154
Claudins and Gastric Cancer: An Overview
HASHIMOTO, I., & Oshima, T. (2022) · Cancers · doi:10.3390/cancers14020290 · Cited by 154
Jovov, B., Itallie, C. M. V., Shaheen, N. J., Carson, J. L., Gambling, T. M., Anderson, J. M., & Orlando, R. C. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00158.2007 · Cited by 149
Rohde, C., Yamaguchi, R., Mukhina, S., Sahin, U., Itoh, K., & Türeci, Ö. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz068 · Cited by 147 · cited 8×
“Moreover, CLDN18-ARHGAP26/6 fusions have been identified in GCs (48).”
BackgroundResultInfluentialHayashi, D., Tamura, A., Tanaka, H., Yamazaki, Y., Watanabe, S., Suzuki, K., Suzuki, K. T., Sentani, K., Yasui, W., Rakugi, H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.10.040 · Cited by 143
Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals
Türeci, Ö., Koslowski, M., Helftenbein, G., Castle, J. C., Rohde, C., Dhaene, K., Seitz, G., & Şahin, U. (2011) · Gene · doi:10.1016/j.gene.2011.04.007 · Cited by 141 · cited 1×
“2) that have highly homologous amino acid sequences (12).”
BackgroundClaudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
Wöll, S., Schlitter, A. M., Dhaene, K., Roller, M., Esposito, I., Sahin, U., & Türeci, Ö. (2014) · International Journal of Cancer · doi:10.1002/ijc.28400 · Cited by 134 · cited 6×
“In addition, it is related to multiple clinicopathological characteristics, including age, sex, chemotherapy resistance, LNM and tumour stage.”
BackgroundInfluentialCharacterization of zolbetuximab in pancreatic cancer models
Türeci, Ö., Mitnacht‐Kraus, R., Wöll, S., Yamada, T., & Şahin, U. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1523096 · Cited by 134
Dottermusch, M., Krüger, S., Behrens, H., Halske, C., & Röcken, C. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02624-7 · Cited by 133
Coati, I., Lotz, G., Fanelli, G. N., Brignola, S., Lanza, C., Cappellesso, R., Pellino, A., Pucciarelli, S., Spolverato, G., Guzzardo, V., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0508-4 · Cited by 131
Claudin-18 Deficiency Results in Alveolar Barrier Dysfunction and Impaired Alveologenesis in Mice
LaFemina, M. J., Sutherland, K., Bentley, T., Gonzales, L. W., Allen, L., Chapin, C. J., Rokkam, D., Sweerus, K. A., Dobbs, L. G., Ballard, P. L., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0456oc · Cited by 124
Claudin-18 Is an Early-Stage Marker of Pancreatic Carcinogenesis
Tanaka, M. H., Shibahara, J., Fukushima, N., Shinozaki‐Ushiku, A., Umeda, M., Ishikawa, S., Kokudo, N., & Fukayama, M. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411420569 · Cited by 118 · cited 5×
“Another study (NCT03874897) enrolled 37 patients with cancer of the digestive system, including 28 with GC, 5 with PDAC and 4 with other cancer types.”
BackgroundInfluentialHagen, S. J., Ang, L., Zheng, Y. Z., Karahan, S. N., Wu, J., Wang, Y. E., Caron, T. J., Gad, A. P., Muthupalani, S., & Fox, J. G. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.041 · Cited by 118 · cited 1×
“Mechanistically, the loss of CLDN18 promotes the rapid development of cancer cells in the stomach of mice, possibly because CLDN18 is a top regulator and effector of the network that regulates the cytokine, stemness, Wnt and Notch signalling pathways (16).”
BackgroundDNA Methylation and Genetic Aberrations in Gastric Cancer
Usui, G., Matsusaka, K., Mano, Y., Urabe, M., Funata, S., Fukayama, M., Ushiku, T., & Kaneda, A. (2020) · Digestion · doi:10.1159/000511243 · Cited by 118 · cited 1×
“ARHGAP26 fusion gene is one of the most frequent somatic genomic rearrangements in gastric cancer, especially in the genomically stable subtype (22, 23).”
BackgroundExpression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer
Jun, K., Kim, J.-H., Jung, J., Choi, H., & Chin, H.-M. (2013) · International Journal of Surgery · doi:10.1016/j.ijsu.2013.11.022 · Cited by 107 · cited 2×
“suggested the loss of claudin-18 as an independent indicator of a poor prognosis in patients with GC, as patients with claudin-18 expression had longer overall survival (OS) than those without claudin-18 expression (27).”
BackgroundZhan, X., Wang, B., Li, Z., Li, J., Wang, H., Chen, L., Jiang, H., Wu, M., Xiao, J., Peng, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2509 · Cited by 107
Oue, N., Sentani, K., Sakamoto, N., & Yasui, W. (2015) · Cancer Science · doi:10.1111/cas.12706 · Cited by 99 · cited 1×
“2, suggesting that the loss of CLDN18 is involved in the pathogenesis of tumours of the intestinal phenotype and indicating that its expression can be used as a marker for the gastric phenotype (28, 41, 46).”
BackgroundKnockout Mice Reveal Key Roles for Claudin 18 in Alveolar Barrier Properties and Fluid Homeostasis
Li, G., Flodby, P., Luo, J., Kage, H., Sipos, A., Gao, D., Ji, Y., Beard, L. L., Marconett, C. N., DeMaio, L., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0353oc · Cited by 92 · cited 2×
“1 is highly expressed in lung alveolar epithelium and is involved in regulating solute and ion permeability, as well as cytoskeletal rearrangement (9).”
BackgroundOshima, T., Shan, J., Okugawa, T., Chen, X., Hori, K., Tomita, T., Fukui, H., Watari, J., & Miwa, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074757 · Cited by 87 · cited 1×
“Subsequent experiments in GC cell lines further confirmed that knockdown of Claudin-18 could significantly promote cell proliferation and invasion, indicating a tumour suppressor role for CLDN18 (14).”
BackgroundClinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer
Baek, J. H., Park, D. J., Kim, G. Y., Cheon, J., Kang, B. W., CHA, H. J., & Kim, J. G. (2019) · Anticancer Research · doi:10.21873/anticanres.13919 · Cited by 83
Zhu, G., Foletti, D. L., Liu, X., Ding, S., Witt, J. M., Hasa-Moreno, A., Rickert, M., Holz, C., Aschenbrenner, L. M., Yang, A. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44874-0 · Cited by 81
Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
Arnold, A., Daum, S., von Winterfeld, M., Berg, E., Hummel, M., Rau, B., Stein, U., & Treese, C. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02380-0 · Cited by 81
Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
Wang, D.-K., Zuo, Q., He, Q., & Li, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705999 · Cited by 74
Shinozaki‐Ushiku, A., Shibahara, J., Noda, N., Tanaka, M. H., Aoki, T., Kokudo, N., & Fukayama, M. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1092-z · Cited by 70 · cited 1×
“9% Up Associated with LNM and poor OS (38)”
BackgroundIto, T., Kojima, T., Yamaguchi, H., Kyuno, D., Kimura, Y., Imamura, M., Takasawa, A., Murata, M., Tanaka, S., Hirata, K., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23095 · Cited by 65
Enrichment of CLDN18‐ARHGAP fusion gene in gastric cancers in young adults
Nakayama, I., Shinozaki, E., Sakata, S., Yamamoto, N., Fujisaki, J., Muramatsu, Y., Hirota, T., Takeuchi, K., Takahashi, S., Yamaguchi, K., et al. (2019) · Cancer Science · doi:10.1111/cas.13967 · Cited by 65 · cited 1×
“These observations indicate that the CLDN18‐ARHGAP fusion is enriched in younger age‐onset GCs, and its presence could contribute to their aggressive characteristics (53).”
BackgroundFinigan, J. H., Faress, J. A., Wilkinson, E., Mishra, R., Nethery, D. E., Wyler, D. K., Shatat, M. A., Ware, L. B., Matthay, M. A., Mason, R. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.208041 · Cited by 61 · cited 1×
“revealed that the NRG-1-HER2/3 signalling pathway participates in IL-1b-mediated lung barrier dysfunction (66).”
BackgroundRHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases
Ushiku, T., Ishikawa, S., Kakiuchi, M., Tanaka, A., Katoh, H., Aburatani, H., Lauwers, G. Y., & Fukayama, M. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0493-0 · Cited by 58
Tanaka, A., Ishikawa, S., Ushiku, T., Yamazawa, S., Katoh, H., Hayashi, A., Kunita, A., & Fukayama, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25464 · Cited by 58 · cited 7×
“Moreover, CLDN18-ARHGAP26/6 fusions have been identified in GCs (48).”
BackgroundInfluentialLate-line treatment in metastatic gastric cancer: today and tomorrow
Smyth, E. C., & Moehler, M. H. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919867522 · Cited by 57
Yano, K., Imaeda, T., & Niimi, T. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00328.2007 · Cited by 55
Shimobaba, S., Taga, S., Akizuki, R., Hichino, A., Endo, S., Matsunaga, T., Watanabe, R., Yamaguchi, M., Yamazaki, Y., Sugatani, J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.02.015 · Cited by 55 · cited 2×
“1 expression was significantly decreased in lung cancer and may play a role in inhibiting tumour progression (19, 20).”
BackgroundClaudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
Wang, X., Zhang, C., Dong, X., Hu, Y., Duan, B., Bai, J., Wu, Y., Fan, L., Liao, X.-H., Kang, Y., et al. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i7.1252 · Cited by 55 · cited 1×
“0% (NT) Up Associated with LNM, DM, nerve invasion, stage; not associated with OS (36)”
BackgroundmiR-1303 Targets Claudin-18 Gene to Modulate Proliferation and Invasion of Gastric Cancer Cells
Zhang, S., Feng, J., Wang, L., Guo, W., Du, Y., Ming, L., & Zhao, G. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3107-5 · Cited by 54 · cited 1×
“Western blot analysis and luciferase reporter assays showed that miR-1303 could markedly attenuate the expression of claudin-18 by binding to the putative binding sites in the CLDN18 mRNA 3’-UTR (70).”
BackgroundSelf-citationAkizuki, R., Shimobaba, S., Matsunaga, T., Endo, S., & Ikari, A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.11.018 · Cited by 53 · cited 1×
“1 could suppress the proliferation and mot i l i t y o f lung ep i the l i a l c e l l s by inh ib i t ing the phosphatidylinositol-3 kinase (PI3K)/pyruvate dehydrogenase kinase-1 (PDK1)/Akt signalling pathway (19, 73).”
BackgroundXu, B., Liu, F., Liu, Q., Shi, T., Wang, Z., Wu, N., Xu, X., Li, L., Fan, X., Yu, L., et al. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-344 · Cited by 52 · cited 1×
“2% Up Associated with age, not a prognostic risk factor for OS; related to GRIN2A mutation (40)”
BackgroundTakasawa, K., Takasawa, A., Osanai, M., Aoyama, T., Ono, Y., Kono, T., Hirohashi, Y., Murata, M., & Sawada, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.033 · Cited by 51
Nair, R. K., & Westin, J. R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_10 · Cited by 51
Zhang, W., Zhang, S., Hou, Q., Qin, Y., Chen, X., Zhou, Z., Shu, Y., Xu, H., & Hu, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01214 · Cited by 48
Self-citationHu, G., Zhu, W., Liu, Y., Wang, Y., Zhang, Z., Zhu, S., Duan, W., Zhou, P., Fu, C., Li, F., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05739-3 · Cited by 43
Soini, Y., Takasawa, A., Eskelinen, M., Juvonen, P., Kärjä, V. J., Hasegawa, T., Murata, M., Tanaka, S., Kojima, T., & Sawada, N. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200400 · Cited by 41
Luo, J., Chimge, N., Zhou, B., Flodby, P., Castaldi, A., Firth, A. L., Liu, Y., Wang, H., Yang, C., Marconett, C. N., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31734 · Cited by 40 · cited 4×
“1 markedly attenuates tumour growth in vivo as well as cell proliferation, migration, invasion and colony formation in vitro (20).”
BackgroundInfluentialFan, L., Chong, X., Zhao, M., Jia, F., Wang, Z., Zhou, Y., Lu, X. J., Huang, Q., Li, P., Yang, Y., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04055 · Cited by 37 · cited 1×
“2 between CTCs and tissue biopsy is 100% (negative: 3 vs 3; positive: 7 vs 7) (42).”
BackgroundIwaya, M., Hayashi, H., Nakajima, T., Matsuda, K., Kinugawa, Y., Tobe, Y., Tateishi, Y., Iwaya, Y., Uehara, T., & Ota, H. (2021) · Histopathology · doi:10.1111/his.14358 · Cited by 37 · cited 1×
“8% NA Associated with LNM; associated with MUC5AC (39)”
BackgroundAnalysis of the expression and genetic alteration of CLDN18 in gastric cancer
Li, J., Zhang, Y., Hu, D., Gong, T.-P., Xu, R., & Gao, J. (2020) · Aging · doi:10.18632/aging.103457 · Cited by 36
Lordick, F., Al‐Batran, S., Ganguli, A. X., Morlock, R., Şahin, U., & Türeci, Ö. (2021) · Gastric Cancer · doi:10.1007/s10120-020-01153-6 · Cited by 36
Hybrid Stomach-Intestinal Chromatin States Underlie Human Barrett’s Metaplasia
Singh, H., Ha, K., Hornick, J. L., Madha, S., Cejas, P., Jajoo, K., Singh, P. N. P., Polak, P. P., Lee, H., & Shivdasani, R. A. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.057 · Cited by 36
miR-767-3p Inhibits Growth and Migration of Lung Adenocarcinoma Cells by Regulating CLDN18
Wan, Y., Dai, H. J., Liu, W., & Ma, H. T. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x15112639918174 · Cited by 35 · cited 8×
“1) is markedly decreased in LUAD and that aged Cldn18 -/- mice have an increased propensity to develop LUAD, CLDN18.”
BackgroundInfluentialTargeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery
Zhao, C., Rong, Z., Ding, J., Wang, L., Wang, B., Ding, L., Lin, M., Meng, X., Wang, F., Yang, Z., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00947 · Cited by 34 · cited 1×
“2 expression (76, 77) or target it as a therapeutic candidate for tumours (78–82).”
BackgroundClaudin-18: unexpected regulator of lung alveolar epithelial cell proliferation
Kotton, D. N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99799 · Cited by 30
Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
Zhong, W., Lu, Y., Ma, Z., He, Y., Ding, Y., Yao, G., Zhou, Z., Dong, J., Fang, Y., Jiang, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885424 · Cited by 29
Matsusaka, K., Ushiku, T., Urabe, M., Fukuyo, M., Abé, H., Ishikawa, S., Seto, Y., Aburatani, H., Hamakubo, T., Kaneda, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11638 · Cited by 28 · cited 1×
“found that the combination of CDH17 and CLDN18 demonstrates homogeneous and robust expression in more than 90% of GC cases, and their coupling is helpful to detect and localise GC metastasis in vivo, which provides a possibility to overcome the challenge of intratumoural heterogeneity (52).”
BackgroundSrisodsai, A., Kurotani, R., Chiba, Y., Sheikh, F. G., Young, H. A., Donnelly, R. P., & Kimura, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405331200 · Cited by 27 · cited 1×
“1, which is a homeodomain-containing transcription factor (59).”
BackgroundYing, S., Chang, D. C., & Lin, S.-L. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-083-0_1 · Cited by 25
The IL1β-HER2-CLDN18/CLDN4 axis mediates lung barrier damage in ARDS
Ma, X., Yu, X., & Zhou, Q. G. (2020) · Aging · doi:10.18632/aging.102804 · Cited by 23
Şahin, U., Al‐Batran, S., Hozaeel, W., Zvirbule, Z., Freiberg‐Richter, J., Lordick, F., Just, M., Bitzer, M., Thuss-Patience, P. C., Krilova, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e15079 · Cited by 22
Espinoza, J. A., Riquelme, I., Sagredo, E. A., Rosa, L., García, P., Bizama, C., Apud‐Bell, M., Leal, P., Weber, H. L., Benavente, F. M., et al. (2018) · Histopathology · doi:10.1111/his.13797 · Cited by 22
1372O CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system
Qi, C., Qin, Y., Liu, D., Gong, J., Ge, S., Zhang, M., Peng, Z., Zhou, J., Zhang, X., Peng, X., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1481 · Cited by 22
A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
Liang, J., Zhang, H., Huang, Y., Fan, L., Li, F., Li, M., Yan, Y., Zhang, J., Li, Z., & Yang, X. (2021) · Cancer Management and Research · doi:10.2147/cmar.s330637 · Cited by 20
Pereira, M. A., Ramos, M. F. K. P., Dias, A. R., Cardili, L., Ribeiro, R. R. E., Castria, T. B. D., Zilberstein, B., Nahas, S. C., Ribeiro, U., & de Mello, E. S. (2021) · Medical Sciences · doi:10.3390/medsci10010004 · Cited by 20
Shen, C., Lin, J.-Y., Lu, C., Yang, S., Peng, C., & Huang, K. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01408-7 · Cited by 19 · cited 2×
“Previous studies have shown that carbonic anhydrase 9 (CAIX), phorbol 12-myristate 13-acetate (PMA), c-jun, epidermal growth factor (EGF) and RAS can upregulate the expression of CLDN18 (15, 55–57) and that interleukin-1b (IL-1b), hyperoxia, STE20/ SPS1-related proline/alanine-rich kinase (SPAK) can inhibit CLDN18 exp…”
BackgroundLi, T., Liu, X., Riederer, B., Nikolovska, K., Singh, A. K., Mäkelä, K. A., Seidler, A., Liu, Y., Gros, G., Bartels, H., et al. (2017) · Acta Physiologica · doi:10.1111/apha.12923 · Cited by 18
Hashimoto, T., Ogawa, R., Tang, T., Yoshida, H., Taniguchi, H., Katai, H., Oda, I., & Sekine, S. (2018) · Modern Pathology · doi:10.1038/s41379-018-0181-9 · Cited by 18 · cited 1×
“found that intestinal-type adenocarcinoma with anastomosing glands, a genetically distinct group of intestinal-type adenocarcinoma, also frequently had CLDN18-ARHGAP fusion (50).”
BackgroundZhang, Z., Liu, X., Zhou, L., Zhang, M., & Liang, Z. (2022) · PubMed · doi:10.14670/hh-18-477 · Cited by 18
Sato, K., Matsumoto, I., Suzuki, K., Tamura, A., Shiraishi, A., Kiyonari, H., Kasamatsu, J., Yamamoto, H., Miyasaka, T., Tanno, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00708-6 · Cited by 17 · cited 1×
“2 are specifically expressed in normal stomach and lung tissues, respectively (13).”
BackgroundXu, G., Qian, N., Liu, Y., Li, H., Yang, C., Wang, J., Wang, F., Chen, L., Bai, G., Xu, Q., et al. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152283 · Cited by 17
Asaka, S., Nakajima, T., Ida, K., Asaka, R., Kobayashi, C., Ito, M., Miyamoto, T., Uehara, T., & Ota, H. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03207-1 · Cited by 15
Akizuki, R., Eguchi, H., Endo, S., Matsunaga, T., & Ikari, A. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00670 · Cited by 12
Klempner, S. J., Lee, K., Metges, J., Catenacci, D. V. T., Loupakis, F., Ilson, D. H., Shah, M. A., Shitara, K., Arozullah, A. M., Park, J. W., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.e16063 · Cited by 7
Park, W., O'Reilly, E. M., Furuse, J., Li, C., Oh, D., García‐Carbonero, R., Roth, G. S., Lee, H.-J., Bhattacharya, P. P., Moran, D. M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.4_suppl.tps782 · Cited by 7
Cited by
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“2-targeting therapies have demonstrated efficacy in clinical trials for GI cancers, including antibodies, antibody-drug conjugates (ADC), and CAR-T cells (64–66).”
BackgroundClaudin 18.2 as a novel therapeutic target
Nakayama, I., Qi, C., Chen, Y., Nakamura, Y., Shen, L., & Shitara, K. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00874-2 · Cited by 210
“The downstream target, activator protein AP-1, has been shown to enhance the translation of claudin 18.2 mRNAs in gastric, pancreatic and bile duct cancer cells 68–70”
InfluentialRecent Advancement in mRNA Vaccine Development and Applications
Al Fayez, N., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 167
Fassan, M., Kuwata, T., Matkowskyj, K. A., Röcken, C., & Rüschoff, J. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100589 · Cited by 72
Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?
Mathias-Machado, M. C., de Jesus, V. H. F., Jacome, A. A. D. A., Donadio, M. D. S., Aruquipa, M. P. S., de Farias, J. P. F., Cunha, R., Silva, L. M. D., & Peixoto, R. D. (2024) · Cancers · doi:10.3390/cancers16030679 · Cited by 79
“…in the TJs [25,32–34] and regulates the permeability to both Na+ and H+ in gastric acid by functioning as a barrier in the gastric mucosa [35], playing a role in cellular polarity, retaining a barrier function, as well as promoting resistance to gastric acid [36]. gastric epithelial cells, CLDN18.”
Background
Metadata
- Authors
- Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X.
- Affiliations
- Zhejiang Cancer Hospital (CN)
- Corresponding author
- Cheng, Xiangdong
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-10
- Volume
- 13
- Pages
- 1132319-1132319
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC10036590
- OpenAlex
- W4323860370
- Cited by
- 78
- References
- 102
- Citations by year
- 2026: 20 · 2025: 22 · 2024: 32 · 2023: 4
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82074245, 81973634)
- Natural Science Foundation of Zhejiang Province (HDMY22H160008)
- Medical Science and Technology Project of Zhejiang Province (2022KY114, WKJ-ZJ-2104)
- Postdoctoral Research Foundation of China (2022M713203)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- claudin 18.2, gastrointestinal cancer, targeted therapy, immunotherapy, tight junctions, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.